NASDAQ · ERAS
Healthcare · Biotechnology
$15.36
Down-$0.89 (-5.48%)
Updated Sep 17, 2026, 7:00 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ERAS closed at $15.36 after 20 trading sessions, down 15.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $16.31 | $16.64 | $15.19 | $15.36 | 6.09M |
| Sep 15, 2026 | $16.135 | $16.29 | $15.535 | $16.25 | 4.69M |
| Sep 14, 2026 | $16.06 | $16.53 | $15.97 | $16.16 | 2.37M |
| Sep 11, 2026 | $16.05 | $16.54 | $15.87 | $15.88 | 2.88M |
| Sep 10, 2026 | $15.37 | $17.25 | $15.37 | $16.03 | 8.25M |
| Sep 9, 2026 | $16.06 | $16.70 | $15.67 | $15.70 | 4.04M |
| Sep 8, 2026 | $15.88 | $16.65 | $15.68 | $16.28 | 4.26M |
| Sep 4, 2026 | $16.04 | $16.40 | $15.77 | $16.19 | 2.06M |
| Sep 3, 2026 | $16.38 | $16.57 | $16.09 | $16.26 | 3.76M |
| Sep 2, 2026 | $16.97 | $17.45 | $15.78 | $16.37 | 5.12M |
| Sep 1, 2026 | $17.58 | $17.95 | $16.68 | $16.76 | 6.71M |
| Aug 31, 2026 | $17.87 | $18.03 | $17.14 | $17.88 | 4.77M |
| Aug 28, 2026 | $19.25 | $19.59 | $18.00 | $18.03 | 2.89M |
| Aug 27, 2026 | $19.30 | $20.40 | $19.14 | $19.49 | 4.12M |
| Aug 26, 2026 | $17.57 | $19.50 | $17.24 | $19.15 | 7.69M |
| Aug 25, 2026 | $17.80 | $18.50 | $17.70 | $17.76 | 2.66M |
| Aug 24, 2026 | $18.41 | $18.66 | $16.88 | $17.60 | 2.24M |
| Aug 21, 2026 | $17.28 | $17.835 | $17.21 | $17.63 | 2.45M |
| Aug 20, 2026 | $17.59 | $17.77 | $16.92 | $17.08 | 2.67M |
| Aug 19, 2026 | $18.77 | $18.77 | $17.705 | $18.07 | 3.31M |
The latest Smart Investors Daily articles mentioning ERAS.
ERAS research
Company profile and research snapshot.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Neutral | — |
| Aug 13, 2026 | Guggenheim | Buy | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 20, 2026 | Morgan Stanley | Equal-Weight | — |
| Jul 14, 2026 | B of A Securities | Neutral | — |
Generated Sep 16, 2026, 9:22 PM
Erasca, Inc. (ERAS) shares declined 5.48% today, falling $0.89 in afternoon trading amid a broader market environment and company presentation activity. The stock's weakness comes as the biotech firm presented at the Morgan Stanley 24th Annual Global Healthcare Conference, though the neutral sentiment around the presentation suggests investors may be digesting updates without significant catalysts.
Bottom line: ERAS's 5.48% decline reflects a combination of sector headwinds and modest investor reception to its Morgan Stanley conference presentation, with no major breakthrough announcements evident. Investors should monitor upcoming clinical trial readouts and regulatory developments as key catalysts, while remaining mindful of the capital intensity and competitive risks inherent in the precision oncology market. The stock's near-term trajectory will likely depend on whether the company can deliver positive data on its pipeline programs.
SeekingAlpha · Sep 15, 2026
Erasca, Inc. (ERAS) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:05 PM EDTCompany ParticipantsJonathan Lim - Co-Founder,...
Yahoo · Sep 10, 2026
Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trial Poster presentation to share nonclinical combination data of ERAS-0015 and ERAS-4001 demonstrating synergy in KRAS G12X-driven models SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on
Yahoo · Sep 8, 2026
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference being held at the New York Marriott Marquis in New York, NY. Management will participate in a fireside chat on Tuesday, September 15, 2026, at 1:05 pm Easte
Yahoo · Sep 4, 2026
On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma. The designation gives Erasca more frequent contact with regulators and, if the drug keeps clearing bars, a shot at accelerated approval, priority review, and rolling review. For a […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ERAS.
